Rapid Qualitative Urine Drug Screen — 12-Parameter Multi-Drug Panel
1 day Rapid Urine Drug Screening Test – a qualitative screening test designed for the simultaneous detection of 12 analytes, including psychoactive substances, certain medicinal products with potential for abuse, and their metabolites.
The test allows the detection of the target substance or a cross-reacting compound in urine at a concentration below or at/above the cut-off threshold established by the manufacturer.
The test is a preliminary screening examination and does not determine the exact concentration of the substance, the dose taken, the time or route of use, or the degree of intoxication.
Panel composition
- MET — methamphetamine (stimulant)
- COC — benzoylecgonine (the main metabolite of cocaine)
- THC — cannabinoid metabolites (cannabis, marijuana)
- BZO — benzodiazepines (e.g. diazepam, alprazolam)
- TCA — tricyclic antidepressants
- BAR — barbiturates (sedative-hypnotic drugs)
- MTD — methadone
- MDMA — 3,4-methylenedioxymethamphetamine (ecstasy)
- PCP — phencyclidine (dissociative psychoactive substance)
- AMP — amphetamines (stimulants)
- OXY — oxycodone (opioid analgesic)
- MOP/OPI — morphine/opioids (morphine, codeine)
Indications
- Suspected recent use of psychoactive substances
- Possible accidental or intentional intake of medicinal products
- Unexplained changes in consciousness or behaviour
- Neurological, cardiovascular, or respiratory symptoms of possible toxicological origin
- Suspected overdose
- Medical monitoring within addiction treatment programs
- Preliminary monitoring of the use of certain medications when medically indicated
Procedure
The test requires a single urine specimen of at least 10 mL, collected in a clean, dry, single-use container without preservatives.
Fasting is not required.
Test method
Immunochromatographic method based on a competitive immunological reaction.
The method allows qualitative detection of the target substance or a cross-reacting compound in relation to the established cut-off threshold.
Result interpretation
The result is classified as negative, preliminary positive, or invalid, according to the manufacturer’s instructions.
A preliminary positive result does not constitute definitive confirmation of the presence of the substance and requires confirmation by a more specific laboratory method.
Important information!
Test results should be interpreted taking into account the clinical presentation, medical history, medications being taken, presumed time of use, and the results of other laboratory and instrumental investigations.
The detection period of substances in urine is approximate and may vary depending on the dose and frequency of use, individual metabolic characteristics, kidney function, urine concentration, time of specimen collection, and the established cut-off value.
This rapid test is a preliminary screening examination. It is not a medical examination for official certification and cannot be used as a stand-alone legal or forensic conclusion.
Medical sources:
https://pmc.ncbi.nlm.nih.gov/articles/PMC4920965/
https://www.sciencedirect.com/topics/medicine-and-dentistry/drug-rapid-test
https://www.tamingthesru.com/blog/diagnostics/urine-drug-screens
https://www.ojp.gov/pdffiles1/Digitization/132364NCJRS.pdf
Preparation:
No special preparation, dietary restrictions, or fasting are required.
Before the test, inform the physician or laboratory staff about all prescription and over-the-counter medications you are taking, dietary supplements, as well as medications used for pain, anxiety, insomnia, or depression, as some substances may affect the screening result or cause cross-reactions.
Excessive fluid intake is not recommended before urine collection, as significant dilution of the specimen may reduce the concentration of the substance being tested below the cut-off threshold.
